CD4 and graft versus host disease: Including also cells to sIL-2R, a 5-parameter biomarker score based on CD4+ T cells, CD8+ T cells, CD19− CD21+ precursor B cells, CD4/CD8 T cell ratio, and sIL-2R was used to predict GVHD onset with AUC of 0.90, SEN of 88.2% and SPE of 66.7% (64).